

## **AVI BioPharma Announces Second Quarter 2010 Financial Results and Corporate Update Conference Call**

August 2, 2010 11:01 AM ET

BOTHELL, WA, Aug 02, 2010 (MARKETWIRE via COMTEX) --

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, will report second quarter 2010 financial results after the NASDAQ Global Market closes on Monday, August 9, 2010. Subsequently, at 5:00 p.m. Eastern time (2:00 p.m. Pacific time), J. David Boyle II, AVI's Interim President and Chief Executive Officer, and Chief Financial Officer, will host a conference call to discuss second quarter 2010 financial results and to provide a corporate update.

The conference call may be accessed by dialing 800.261.3417 for domestic callers and 617.614.3673 for international callers. The passcode for the call is 43924630 and please specify to the operator that you would like to join the "AVI BioPharma second quarter 2010 earnings call." The conference call will be webcast live under the events section of AVI's website at [www.avibio.com](http://www.avibio.com), and will be archived there following the call. Please connect to AVI's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

### About AVI BioPharma

AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Applying pioneering technologies developed and optimized by AVI, we are able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike other RNA-based approaches, our technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins. By leveraging our highly differentiated RNA-based technology platforms, we have built a pipeline of potentially transformative therapeutic agents, including a clinical stage Duchenne muscular dystrophy candidate and anti-infective candidates for influenza and hemorrhagic fever viruses. For more information, visit [www.avibio.com](http://www.avibio.com).

SOURCE: AVI BioPharma, Inc.